Abstract

<div>Abstract<p><b>Background:</b> Adipocytokines, adipocyte-secreted hormones, play a critical role in breast cancer development. The expression of visfatin, a newly discovered adipocytokine, in breast cancer tissues was determined and correlated with patient clinicopathologic variables.</p><p><b>Methods:</b> Visfatin expression in breast cancer tissues was analyzed by immunohistochemistry. Visfatin expression was correlated with clinicopathologic variables as well as recurrence rates, using the χ<sup>2</sup> test. The prognostic value of visfatin for disease-free and overall survival was evaluated by Kaplan–Meier estimates, and the significance of differences between curves was evaluated by the log-rank test.</p><p><b>Results:</b> High visfatin expression in breast cancer tissues was significantly correlated with tumor size, estrogen receptor (ER) negativity, and progesterone receptor (PR) negativity. Hormone therapy, but not radiotherapy or chemotherapy, decreased the recurrence rate in patients with high visfatin expression. Whereas high visfatin expression alone was associated with poor disease-free and overall survival, worse disease-free and overall survival was observed when high visfatin expression was combined with ER- and PR-negative status. Cox regression analysis also revealed that visfatin is an independent predictor of disease-free and overall survival.</p><p><b>Conclusion:</b> High visfatin expression in breast cancer tissue is associated with more malignant cancer behavior as well as poor patient survival.</p><p><b>Impact:</b> Visfatin is an independent prognosis predictor for breast cancer. <i>Cancer Epidemiol Biomarkers Prev; 20(9); 1892–901. ©2011 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.